Efficacy and safety of *Andrographis paniculata* extract in patients with mild COVID-19: A randomized controlled trial

Kulthanit Wanaratna\(^a\), Pornvimol Leethong\(^b\), Nitapha Inchai\(^a\), Wararat Chueawiang\(^a\), Pantitra Sriraksa\(^a\), Anutida Tabmee\(^a\), Sayomporn Sirinavin\(^c\)

\(^a\)Department of Thai Traditional and Alternative Medicine, Ministry of Public Heath, Thailand

\(^b\)Samutprakarn Hospital, Ministry of Public Heath, Thailand

\(^c\)Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand

Corresponding author:

Kulthanit Wanaratna, MD.

Department of Thai Traditional and Alternative Medicine

Ministry of Public Heath, Thailand

E-mail: kulthanitw@gmail.com
ABSTRACT

Objective: To assess the efficacy and safety of Andrographis paniculata extract (APE) in adults with mild COVID-19.

Methods: The alcoholic extract of the aerial part of A. paniculata was used. In this randomized, double-blinded, placebo-controlled trial, adults with laboratory-confirmed COVID-19, and mild symptoms were randomized 1:1 to receive APE (60 mg andrographolide, t.i.d, for 5 days) versus placebo, plus standard supportive care. Blood tests for CRP, liver and renal assessment were performed on Days 1, 3, and 5. The outcomes were occurrence of pneumonia detected by chest X-ray, nasopharyngeal SARS-CoV-2 detection by rRT-PCR, changes of CRP levels, and adverse drug reactions.

Results: Patients were randomized to receive APE (n=29) or placebo (n=28). Pneumonia occurrence during illness was 0/29 (0%) versus 3/28 (10.7%), (p=0.039); and patients with nasopharyngeal SARS-CoV-2 detection on Day 5 were 10/29 (34.5%) versus 16/28 (57.1%), (p=0.086), for those who received APE and placebo, respectively. All three patients with pneumonia had substantially rising serum CRP; and high CRP levels on Day 5. None had evidence of liver or renal impairment.

Conclusion: This APE-extract treatment regimen was potentially effective and safe in adults with mild COVID-19. The rising of CRP suggested disease progression. Further studies are needed.

Keywords: Andrographis paniculata; COVID-19; SARS-CoV-2; randomized controlled trial; C-reactive protein; pneumonia
INTRODUCTION

Coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic of the highest priority (World Health Organization, 2021). Clinical spectrum of the disease is categorized into asymptomatic, mild, moderate, severe, and critical illness. About 80% of cases are classified as asymptomatic and mild (fever or upper respiratory tract symptoms, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste or smell, but without pneumonia), or moderate (pneumonia, with oxygen saturation ≥94% on room air). Mild COVID-19 may worsen to moderate and severe disease, whilst lower respiratory tract involvement presenting as pneumonia is the primary indicator of more severe diseases besides multi-organ dysfunction or failure (Wu and McGoogan, 2020; National Institute of Health USA, 2021). Predictors of a worse outcome in COVID-19 patients include host factors (e.g., gender, age, co-morbidities), disease characteristics (Wu and McGoogan, 2020; National Institute of Health USA, 2021), and laboratory parameters such as C-reactive protein (CRP) which is an inflammatory marker (Mueller et al., 2020; Potempa et al., 2020; Wang, 2020; Stringer et al., 2021). In normal healthy individuals, baseline CRP levels in the blood are reported to be less than 10 μg/mL (World Health Organization, 2014; Wang, 2020). The main mechanisms of disease progression in COVID-19 are intracellular viral replication causing cell lysis or cell death, and hyperactivation of immune responses contribute to widespread hyperinflammation (van Eijk et al., 2021). In addition to symptomatic management of patients with mild COVID-19, a therapeutic drug that would limit the course of infection is urgently needed.

Andrographis paniculata (Burm.f.) Wall. ex Neesis is an annual herb native to the Indian subcontinent and widely introduced, naturalized, and cultivated in Southeast Asia and China (Plant of the World Online, 2019). It is one of the commonly used medicinal plants in Indian Ayurvedic medicine, Chinese and Thai traditional medicines, for the treatment of acute upper respiratory tract infection and diarrhea (National Drug Committee, Thailand 2000; the State Pharmacopoeia Commission of the People’s Republic of China, 2015; Banerjee et al., 2021). Its name in Thai is Fa Thalai Chon. The main constituent of A. paniculata is andrographolide which is a bioactive diterpene lactone. The adverse effects include headache, fatigue, allergic reactions, nausea, and diarrhea, which are uncommon; while more severe adverse effects, although very rare, are urticaria or anaphylaxis (Thamlikitkul et al., 1991;
Worakunphanich et al., 2021). The therapeutic efficacy of A. paniculata is due to its various pharmacological activities, i.e., antiviral, anti-inflammatory, antipyretic, and immune regulation activities (Dai et al., 2019). *In silico* studies revealed that andrographolide is an inhibitor of the main protease of SARS-CoV-2 (Murugan et al., 2020; Shi et al., 2020; Enmozhi et al., 2021; Hiremath et al., 2021). Furthermore, *in vitro* study also demonstrated that it acts on SARS-Cov-2 by preventing viral replication in cells. (Phumiamorn S, 2020; Sa-Ngiamsuntorn et al., 2021). Due to its *in vitro* anti-SARS-CoV-2 activity together with the potential benefits of its various pharmacological activities especially anti-inflammation, we explored its treatment effects on mild COVID-19 volunteers in a small group (n=6), and the results were very promising. A substantial reduction of viral replication in volunteers was detected. Therefore, this randomized, double-blind, placebo-controlled trial was conducted to determine the efficacy and safety of oral A. paniculata extract among adults with mildly symptomatic SARS-CoV-2 infection. In addition, we explored the role of serum CRP in prediction of disease progression in mild COVID-19.

**Patients and Methods**

This trial was approved by the Ethics Committee for Research in Human Subjects in the Fields of Thai Traditional and Alternative Medicine (No.12-2563). During the study period (December 2020 - March 2021), all Thais coming back to Thailand were state quarantined and subjected to nasopharyngeal swabs for real-time reverse transcription polymerase chain reaction (rRT-PCR) test for SARS-CoV-2. Those who tested positive were promptly admitted to state quarantine hospitals, of which two of them in central Thailand (SamutPrakan Hospital and Nakhon Pathom Hospital) were the study sites.

**Patients**

The patient inclusion criteria were (1) age 18–60 years; with (2) diagnosis of SARS-CoV-2 infection by positive rRT-PCR test; (3) being admitted to hospital within 72 hours of illness; (4) presence of any signs and symptoms of mild COVID-19 (e.g., fever, cough, sore throat, malaise, headache, and diarrhea); and (5) not having signs and symptoms of pneumonia or abnormal chest imaging. Patients were excluded if they (1) had any underlying medical conditions that increase the risk of severe COVID-19; (2) had any conditions for which using A. paniculata should be avoided, i.e., history of allergy to A. paniculata, taking antihypertensive or anticoagulant drugs, or being pregnant or lactating; or (3) were receiving any antiviral drug.
Methods

The standardized alcoholic extract of the aerial part of A. paniculata (APE, AP extract) was used. Each capsule of APE contains 20 mg of andrographolide. Both APE and placebo capsules were produced by Thai Herbal Products Co., Ltd, Thailand, and they were indistinguishable.

The patients were randomized 1:1, with six-block randomization using a computer program, to receive oral APE or placebo within 24 hours after admission, with similar standard supportive care in both groups following the national clinical practice guideline. The APE-treatment patients received 3 capsules (60 mg. andrographolide) of APE, 3 times a day (t.i.d.), for 5 days. The placebo-control patients received 3 capsules of placebo orally, t.i.d., for 5 days.

Outcome assessment

Chest X-rays were assessed on Days 1, 3, and 5. For those without abnormal chest X-rays by Day 5 who had progression of respiratory symptoms, additional chest X-rays would be performed. Nasopharyngeal swabs were repeated on Day 5 for the presence of SARS-CoV-2 by rRT-PCR. Venous blood tests, including complete blood count, blood urea nitrogen and creatinine, aspartate aminotransferase and alanine aminotransferase, and CRP, were performed on enrolment, days 1, 3, and 5. Suspected clinical adverse effects of drugs were recorded.

Statistical analysis

Data were described by mean with standard deviation (mean±SD) or frequency (%), for continuous or categorical data, respectively. Characteristics of patients were compared between groups by Student t-test or Chi-square test for continuous or categorical data, respectively. All analyses were performed by STATA version 16.0, and p-value <0.05 was considered as statistically significant.

Results

Fifty-seven of the 63 enrolled patients completed the study, resulting in 29 patients in the APE-treatment group and 28 patients in the placebo-control group. Three patients of each group withdrew during the study, due to unwillingness for further blood testing (1 control, 2 APE-treatment) and unpleasant symptoms (1 palpitation in control, 1 nausea, and 1 diarrhea in APE-treatment); while none of them developed pneumonia. The baseline characteristics (age, gender, etc.)...
body mass index, and CRP level on enrollment), were comparable between the 2 groups (Table 1). The average ages of the APE-treatment and placebo-control group were 39.3±11.0 and 39.4±11.6 years, respectively (p=0.949).

Table 2 demonstrates the occurrence of pneumonia, detection of nasopharyngeal SARS-CoV-2, and CRP levels ≥10 mg/L. None of the patients in the APE-treatment group, but 3 patients in the control group developed pneumonia (on Days 6-7 after admission), being 0/29 (0%) versus 3/28 (10.7%), (p=0.039). On Day 5 of the trial, SARS-CoV-2 from nasopharyngeal swab was detected by rRT-PCR in 10/29 (34.5%) patients of the APE-treatment group, and 16/28 (57.1%) patients of the control group, (p=0.086).

None of the APE-treatment group had CRP >10 mg/L during the study period. In the control group, 2 patients had high CRP levels on admission (18.3 and 18.4 mg/L), and one who had rising CRP levels developed pneumonia while another with steady CPR levels did not. Three patients who had pneumonia had substantially rising serum CRP on Day 3 and high CRP of 13.9, 20.7, and 21.0 mg/L on Day 5. In addition, 2 patients in the control group had rising CRP and high CRP of 16.0 and 16.1 mg/L on Day 5, respectively, but did not have pneumonia.

Abnormal symptoms as possible AP adverse effects were found in 2 patients in the APE-treatment group, and both were mild and self-limited gastrointestinal tract symptoms (1 nausea, 1 diarrhea), and one patient in the placebo group had palpitation. None of the patients in both groups had evidence of substantial hematology, liver or renal function impairment.

DISCUSSION

Our study suggests that the regimen of APE treatment (oral 60 mg of andrographolide, t.i.d., for 5 days) should be given early in adults with mild COVID-19, without risk for severe COVID-19 by host factors, which prevents disease progression to more severe COVID-19, by using pneumonia as the indicator. In addition, adverse effects from the treatment are uncommon and benign. Our study showed a tendency of more rapid SARS-CoV-2 clearance in the APE-treatment group than the placebo-control group, although the difference did not reach the statistically significant level which was likely due to the small sample size. A recent comprehensive review on antimicrobial pharmacology, clinical safety, and efficacy of Andrographis paniculata, demonstrated its high potential for effective and safe COVID-19 treatment, and there was a need for clinical data. (Hossain et al., 2021).
The findings of this study on serum CRP levels in mild COVID-19 patients agree with the previous retrospective study in 27 adults in the early stage of COVID-19 that CRP levels were low in mild disease and increased with disease progression (Wang, 2020). There were also suggestions that increasing CRP levels during the first 48-to-72 hours of hospitalization was a better predictor of respiratory deterioration than initial CRP levels, while steady CRP levels were observed in patients whose condition remained stable (Mueller et al., 2020).

The study demonstrates APE-treatment efficacy on prevention of mild COVID-19 progression and probable shortening of viral shedding period. The treatment benefit is likely to be the result of the action of andrographolide and its derivatives as anti-SARS-CoV-2 activity by early inhibiting intracellular viral replication which causes cell damage and inflammation. The treatment needs to follow the prescribed regimen and daily recommended dose.

This clinical trial used a strong clinical research methodology, as double-blinded RCT, in efficacy assessment of an APE-treatment regimen in mild COVID-19 adults. The study was limited by the small sample size due to changing situation of COVID-19 epidemic waves.

**Conclusion**

This double-blind RCT suggests a promising efficacy of early treatment with the study AP-extract treatment regimen for mild COVID-19 in the prevention of disease progression. Adverse drug effects are mild, self-limited, and uncommon. Further studies are required to confirm these findings.

**Acknowledgments**

The authors gratefully acknowledge the study team, at SamutPrakan Hospital and Nakhon Pathom Hospital, who involved in this study; Dr. MarutJirasetsiri and Dr. AmpornBenjaponpitak, Department of Thai traditional and Alternative Medicine, for their full encouragement and support.

We would like to thank Stephen John Pinder for conducting a language review on this manuscript.

**Financial support.** This research project was supported by Thai Traditional Medical Knowledge Fund.
Potential conflicts of interest. The authors have no conflicts of interest to declare.

References


Table 1 Baseline characteristics of patients who received *Andrographis paniculata* extract (AP-extract) or placebo

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>AP-extract (n=29)</th>
<th>Placebo (n=28)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age(years), mean ± SD</td>
<td>39.3±11.4</td>
<td>39.4±11.6</td>
<td>0.9487</td>
</tr>
<tr>
<td>Male; n (%)</td>
<td>12(41.4)</td>
<td>11 (39.3)</td>
<td>0.870</td>
</tr>
<tr>
<td>BMI (kg/m$^2$), n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Underweight or normal weight</td>
<td>19 (65.5)</td>
<td>15 (53.6)</td>
<td>0.684</td>
</tr>
<tr>
<td>- Overweight (BMI 25-29.9 kg/m$^2$)</td>
<td>7 (24.1)</td>
<td>9 (32.1)</td>
<td></td>
</tr>
<tr>
<td>- Moderate Obesity (BMI ≥ 30-34.9 kg/m$^2$)</td>
<td>3 (10.3)</td>
<td>4 (14.3)</td>
<td></td>
</tr>
<tr>
<td>- Severe Obesity (BMI &gt; 35 kg/m$^2$)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>CRP levels on hospital admission, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- ≤5 mg/L</td>
<td>24 (82.8)</td>
<td>22 (78.6)</td>
<td>0.495</td>
</tr>
<tr>
<td>- &gt;5-10 mg/L</td>
<td>5 (17.2)</td>
<td>4 (14.3)</td>
<td></td>
</tr>
<tr>
<td>- &gt;10-18 mg/L</td>
<td>0 (0.0)</td>
<td>2* (7.1)</td>
<td></td>
</tr>
</tbody>
</table>

BMI = body mass index, CRP = C-reactive protein

*One patient with rising CRP levels developed pneumonia, the other with steady CRP levels did not.
Table 2 Occurrence of pneumonia, day-5 SARS-CoV-2 detection and C-reactive protein (CRP) levels >10 mg/L in patients who received Andrographis paniculata extract (AP-extract) or placebo

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>AP-extract n=29</th>
<th>Placebo n=28</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumonia, n (%)</td>
<td>0 (0.0)</td>
<td>3 (10.7)</td>
<td>0.039</td>
</tr>
<tr>
<td>Positive SARS-CoV-2 detection, n (%)</td>
<td>10 (34.5)</td>
<td>16 (57.1)</td>
<td>0.086</td>
</tr>
<tr>
<td>CRP &gt;10 mg/L on Day 5, n (%)</td>
<td>0 (0.0)</td>
<td>5* (17.9)</td>
<td>0.023</td>
</tr>
</tbody>
</table>

* 3 patients developed pneumonia